AFL — Aflac Incorporated

The tape and the sell-side say the same thing: no one is excited. Q2 2026 (reported August 2026) delivered adjusted EPS of $1.75, a narrow miss versus the $1.76-$1.78 consensus; total revenue of ~$4.22B beat on the top line but was roughly flat to down year over year. Management flagged Japan sales -5.6% YoY (tough comparison), the Japan full-year benefit ratio landing at the high end of 60-63% (ex the actuarial review), and cut U.S. net earned premium growth guidance to 'just below' the original 3-6% range. Offsetting that, Aflac returned $1.3B to shareholders in Q2 and is repositioning ~$4.8B of the investment portfolio for a >$50M run-rate net investment income lift. Ratings split roughly 9 buy / 18 hold / 5 sell, with Wolfe Research initiating at Underperform/$103 (arguing EPS growth now leans on buybacks rather than organic earnings) against Piper Sandler and Raymond James at $123-$138. Targets averaging $116-$119 against a $115.28 price means the market sees roughly zero expected return over the next year.

Reported quarterly revenue is too noisy to read as a core trend: YoY swings across the last eight quarters ran from -39.7% (Q3 2024) to +57.9% (Q3 2025), because GAAP revenue carries net investment gains/losses, FX and portfolio repositioning effects. What actually matters: (1) Q2 2026 revenue of $4,083M versus $4,218M in Q2 2025 is -3.2% YoY on the dataset (the brief cites ~$4.22B, -1.0% YoY) — either way, flat-to-down, with U.S. net earned premium growth guidance cut to 'just below' 3-6%; (2) Japan sales -5.6% YoY in Q2 2026 with the benefit ratio guided to the high end of 60-63%; (3) GAAP diluted EPS has been dominated by realized gains from the switch trades — $3.08 (Q3 2025), $2.59 (Q4 2025), $1.98 (Q1 2026) — versus a much more modest $1.63 GAAP / $1.75 adjusted in Q2 2026, which missed consensus. The balance sheet, by contrast, is compounding steadily: stockholders' equity rose from $26.05B (Q2 2024) to $30.31B (Q2 2026), roughly +7.9% annualized, helped by AOCI recovery, while long-term debt rose from $7.24B (Q4 2023) to $8.73B (Q2 2026) and cash sits at $6.12B. Verdict: stable to slowly decelerating core, no inflection in either direction — the revenue 'trend' is an accounting artifact, not a business signal.

As of 2026-09-13 at $115.28, Aflac screens at a 12.37x TTM P/E — cheap-looking until you notice TTM EPS of $9.644 is inflated by realized investment gains tied to the $4.8B portfolio repositioning. On the forward adjusted EPS figure in the dataset ($7.01), the forward P/E is roughly 16.4x for low-single-digit underlying growth, versus a 5-year average TTM P/E of 11.35x and a 5-year average P/S of 2.64 against a current 3.24 (a ~23% premium). P/B is 1.92x on roughly $59.55 of book value per share, and the 2.07% dividend yield sits near the low end of Aflac's own historical yield band. The 0.113 PEG ratio is a data artifact, not evidence of cheapness. Verdict: fairly valued at best, and in reality modestly expensive — the market is paying a defensive-quality premium, which is exactly why the deterministic score tags it 'Rich vs. its own history.'

At $115.28 the price embeds ~16.4x forward adjusted EPS of $7.01 and a 2.07% yield — in other words, the market has already paid for the buyback-driven EPS compounding ($1.3B returned in Q2 2026 alone) and the >$50M run-rate NII lift, not for organic growth. That leaves little cushion: another cut to U.S. premium growth or a Japan sales miss could compress the multiple toward 13-14x, which on $7.01 is $91-$98. Conversely, a clean Q3 actuarial review plus a Japan sales rebound would let the market defend 15-16x ($105-$112). The daily tell is the gap between GAAP and adjusted EPS — a widening gap means realized gains rather than earnings power are driving the headline, and the TTM multiple is lying to you.

As of 2026-09-13, RSI(14) was 39.35 — weak but not oversold — with price 1.56% below the 20-day SMA (~$117.1) and 4.87% below the 50-day SMA (~$121.2), yet 0.54% above the 200-day SMA (~$114.7; levels derived from the given percentage gaps). One-month return of -4.51% and three-month of -2.14% against a six-month +6.04% says the intermediate uptrend has stalled into a pullback rather than broken down. Implication: no urgency to buy here. The 200-day is the line that matters — a decisive break below it confirms the downtrend, while reclaiming the 50-day near $121 is the constructive signal. The better entry would be RSI under 30 with the 200-day still intact, or a return toward the low-$100s where the valuation actually works.

• Higher Japanese interest rates and a steepening JGB curve — management explicitly calls this supportive, since it lifts reinvestment yields on Aflac's large yen-denominated fixed-income book and is the main structural tailwind for the Japan segment.
• Yen/USD FX translation — a material share of revenue and earnings is yen-denominated, so reported USD revenue and EPS can fall even when Japan operations are stable in local currency; persistent FX volatility is a structural drag on reported numbers.
• U.S. credit spreads and rate volatility — Aflac's float is invested in fixed income, so spread widening or another rate shock hits AOCI and book value (stockholders' equity rose from $22.0B at year-end 2023 to $30.3B at Q2 2026 partly on AOCI recovery, and that can reverse).
• Defensive/low-beta sector rotation — a beta of 0.58 makes AFL a funding source in risk-on markets and a haven in risk-off ones, so flows are driven as much by macro regime and rate expectations as by company fundamentals.
• Dual-market regulation — Japan's FSA oversight of third-sector products (plus any change to the tax treatment that drives medical/cancer sales) and U.S. state insurance regulation of supplemental health products are both live, slow-moving risks.

• Q3 2026 earnings (typically late October/early November 2026) — the annual actuarial assumption review is the single largest swing factor for the Japan benefit ratio and EPS; management has guided the full-year Japan benefit ratio to the high end of 60-63% excluding that review.
• Evidence that the $4.8B portfolio switch trades actually deliver the targeted >$50M run-rate net investment income lift in reported results.
• A Japan sales rebound toward management's goal of exceeding full-year 2025 sales, after the -5.6% YoY decline in Q2 2026.
• U.S. net earned premium growth stabilizing near, or back inside, the original 3-6% guidance range after being revised to 'just below.'
• Continued capital return — the $0.61 quarterly dividend (paid September 1, 2026) plus roughly $1B/quarter of buybacks; a dividend increase announcement would be a clean positive signal.

• Japan's third-sector engine is structurally maturing — Wolfe Research's Underperform/$103 call argues EPS growth now depends on share buybacks rather than organic earnings, and Japan sales fell 5.6% YoY in Q2 2026.
• Actuarial assumption review risk — a reserve strengthening or benefit-ratio charge in the Q3 2026 review would hit both EPS and book value in one print.
• U.S. premium growth guidance has already been cut once (to 'just below' 3-6%); a second cut would undercut the entire defensive-compounder narrative.
• Valuation/expectation risk — ~16.4x forward adjusted EPS ($7.01) against a 5-year average TTM P/E of 11.35x leaves little room for error, and the headline 12.4x TTM P/E flatters the stock because TTM EPS includes realized investment gains.
• Yen weakness and credit spread widening — both flow straight through to reported revenue, EPS and AOCI/book value (currently 1.92x P/B), and both are outside management's control.

Not a buy at $115.28, but not a sell either. Aflac is a genuinely defensive, low-beta annuity: no leverage problem (D/E 0.29), $6.12B of cash, a 32% operating margin, a 2.07% dividend, and a Japan book now reinvesting into higher yields. The problem is the price — roughly 16.4x forward adjusted EPS for 3-5% growth, a yield near the low end of its own range, freshly cut U.S. premium guidance, and Japan sales down 5.6%. I'd need either a price closer to $103 (my calculated fair value) or evidence of a Japan sales inflection plus a benign Q3 actuarial review before treating this as anything more than a dividend-hold.

Blended three ways on the 2026-09-13 data: (1) 14.5x forward adjusted EPS of $7.01 = $101.6 (60% weight) — a deliberate discount to the market's ~16.4x, reflecting Japan's -5.6% Q2 sales decline, the U.S. premium guidance cut and the Q2 adjusted EPS miss, but a premium to life-insurer peers for the 0.58 beta, fortress balance sheet and steady buyback; (2) dividend-yield cross-check: $2.44 annualized dividend divided by a 2.35% fair yield = $103.8 (20% weight); (3) P/B cross-check: a 1.75x justified multiple on $59.55 book value per share = $104.2 (20% weight). Weighted result ≈ $102.6, rounded to $103 — roughly 11% below the $115.28 price and below the $116-$119 sell-side consensus.